Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-10 Long-Term Safety and Efficacy of Plozasiran in Hypertriglyceridemia
jRCT2031250633Phase 3Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of plozasiran in hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Started Feb 2026; status: active, not recruiting.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on jRCT2031250633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250633.